Levi & Korsinsky reminds shareholders of Grail, Inc. that the lead plaintiff deadline is August 4, 2026 in a securities class action. The lawsuit is on behalf of investors who purchased Grail securities between May 13, 2025 and February 19, 2026. Grail shares fell 50.55%, losing $51.32 per share, on February 20, 2026 after the company disclosed the primary endpoint of statistically significant Stage III-IV cancer reduction was not observed in the NHS-Galleri trial. The complaint alleges that analyst models were built on incomplete and misleading company disclosures, and that management withheld detailed top-line data citing trial integrity concerns. Investors who suffered losses may contact the firm for a free evaluation.
GRAIL, LLCSecurities class action lawsuit and lead plaintiff deadline for Grail investors, alleging misleading disclosures about trial results.